[go: up one dir, main page]

DE122006000044I1 - Hemmung der Anheftung von Lymphocyten an das Gefässendothel mittels einer neuen extrazellulären Matrixrezeptor-Ligand-Wechselwirkung - Google Patents

Hemmung der Anheftung von Lymphocyten an das Gefässendothel mittels einer neuen extrazellulären Matrixrezeptor-Ligand-Wechselwirkung

Info

Publication number
DE122006000044I1
DE122006000044I1 DE1990634116 DE69034116C DE122006000044I1 DE 122006000044 I1 DE122006000044 I1 DE 122006000044I1 DE 1990634116 DE1990634116 DE 1990634116 DE 69034116 C DE69034116 C DE 69034116C DE 122006000044 I1 DE122006000044 I1 DE 122006000044I1
Authority
DE
Germany
Prior art keywords
receptor
lymphocytes
present
beta
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1990634116
Other languages
English (en)
Other versions
DE69034116T2 (de
DE69034116D1 (de
DE69034116T3 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23591680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122006000044(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of DE122006000044I1 publication Critical patent/DE122006000044I1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE1990634116 1989-09-01 1990-08-31 Hemmung der Anheftung von Lymphocyten an das Gefässendothel mittels einer neuen extrazellulären Matrixrezeptor-Ligand-Wechselwirkung Pending DE122006000044I1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40238989A 1989-09-01 1989-09-01
PCT/US1990/004978 WO1991003252A1 (en) 1989-09-01 1990-08-31 Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction

Publications (1)

Publication Number Publication Date
DE122006000044I1 true DE122006000044I1 (de) 2007-04-19

Family

ID=23591680

Family Applications (3)

Application Number Title Priority Date Filing Date
DE122006000044C Active DE122006000044I2 (de) 1989-09-01 1990-08-31 Hemmung der Anheftung von Lymphocyten an das Gefässendothel mittels einer neuen extrazellulären Matrixrezeptor-Ligand-Wechselwirkung
DE1990634116 Pending DE122006000044I1 (de) 1989-09-01 1990-08-31 Hemmung der Anheftung von Lymphocyten an das Gefässendothel mittels einer neuen extrazellulären Matrixrezeptor-Ligand-Wechselwirkung
DE69034116.4T Expired - Lifetime DE69034116T3 (de) 1989-09-01 1990-08-31 Hemmung der anheftung von lymphozyten an das gefässendothelium mittels einer neuen extrazellulärer matrixrezeptor-ligand-wechselwirkung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE122006000044C Active DE122006000044I2 (de) 1989-09-01 1990-08-31 Hemmung der Anheftung von Lymphocyten an das Gefässendothel mittels einer neuen extrazellulären Matrixrezeptor-Ligand-Wechselwirkung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69034116.4T Expired - Lifetime DE69034116T3 (de) 1989-09-01 1990-08-31 Hemmung der anheftung von lymphozyten an das gefässendothelium mittels einer neuen extrazellulärer matrixrezeptor-ligand-wechselwirkung

Country Status (19)

Country Link
EP (2) EP0489837B2 (de)
JP (1) JP3357359B2 (de)
KR (1) KR100188459B1 (de)
AT (1) ATE253642T1 (de)
AU (1) AU654657B2 (de)
CA (1) CA2065292C (de)
DD (1) DD297562A5 (de)
DE (3) DE122006000044I2 (de)
DK (1) DK0489837T4 (de)
ES (1) ES2210225T5 (de)
FI (2) FI116793B (de)
GR (2) GR1001372B (de)
IE (2) IE903169A1 (de)
IL (3) IL113261A (de)
LU (1) LU91273I2 (de)
NL (1) NL300240I2 (de)
NZ (1) NZ235131A (de)
PT (1) PT95180A (de)
WO (1) WO1991003252A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5730978A (en) * 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
AU3420693A (en) * 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
CA2127462C (en) * 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
IL102646A (en) * 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
EP0670735B1 (de) 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripheralisierung hämatopoietischer stammzellen
JP3593343B2 (ja) † 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
AU688307B2 (en) † 1993-03-18 1998-03-12 N.V. Innogenetics S.A. Process for typing HLA-B using specific primers and probes sets
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
US5821231A (en) * 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
WO1995019790A1 (en) * 1994-01-25 1995-07-27 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
FR2724393A1 (fr) * 1994-09-12 1996-03-15 Inst Nat Sante Rech Med Obtention d'un anticorps monoclonal recombinant humanise a partir d'un anticorps monoclonal murin, sa production en cellules d'insecte, et ses utilisations
WO1997035557A1 (en) * 1996-03-22 1997-10-02 Kao Corporation External skin-care composition
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP1485127B1 (de) 2002-02-25 2011-06-08 Elan Pharmaceuticals, Inc. Verabreichung von mitteln zur behandlung von entzündungen
US7125650B2 (en) 2004-07-20 2006-10-24 Roberts David H Method for bump exposing relief image printing plates
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP3311834A1 (de) 2011-05-02 2018-04-25 Millennium Pharmaceuticals, Inc. Formulierung für anti-alpha4beta7-antikörper
EP4597110A3 (de) * 2024-02-05 2025-09-10 Universita' degli studi di Brescia Hypermobiles ehlers-danlos-syndrom, hypermobilitätsspektrumsstörungen und osteoarthritis-plasmamarker

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
WO1990008833A1 (en) * 1989-02-02 1990-08-09 Massachusetts Institute Of Technology Expression of recombinant fibronectin in genetically engineered cells

Also Published As

Publication number Publication date
FI920899A0 (fi) 1992-02-28
EP1366769A1 (de) 2003-12-03
GR900100648A (en) 1992-01-20
AU654657B2 (en) 1994-11-17
ES2210225T5 (es) 2014-02-04
IL113261A (en) 1996-10-16
GR1001372B (el) 1993-10-29
DD297562A5 (de) 1992-01-16
ATE253642T1 (de) 2003-11-15
PT95180A (pt) 1991-05-22
IE20040028A1 (en) 2004-05-05
JPH05503070A (ja) 1993-05-27
DK0489837T3 (da) 2004-03-01
NL300240I2 (nl) 2007-03-01
ES2210225T3 (es) 2004-07-01
FI116793B (fi) 2006-02-28
JP3357359B2 (ja) 2002-12-16
DE69034116T2 (de) 2004-08-26
FI20050941L (fi) 2005-09-21
IL113261A0 (en) 1995-07-31
KR100188459B1 (ko) 1999-06-01
EP0489837B2 (de) 2013-11-13
FI118842B (fi) 2008-04-15
KR920703086A (ko) 1992-12-17
DE69034116D1 (de) 2003-12-11
AU6354290A (en) 1991-04-08
CA2065292A1 (en) 1991-03-02
DE69034116T3 (de) 2014-06-18
LU91273I2 (fr) 2006-10-10
EP0489837A4 (en) 1993-06-16
EP0489837A1 (de) 1992-06-17
WO1991003252A1 (en) 1991-03-21
DE122006000044I2 (de) 2011-01-13
NZ235131A (en) 1993-03-26
DK0489837T4 (da) 2013-11-18
EP0489837B1 (de) 2003-11-05
IL95501A (en) 1997-04-15
GR1001161B (el) 1993-05-24
NL300240I1 (nl) 2006-10-02
IE903169A1 (en) 1991-03-13
CA2065292C (en) 2001-05-29

Similar Documents

Publication Publication Date Title
DE122006000044I1 (de) Hemmung der Anheftung von Lymphocyten an das Gefässendothel mittels einer neuen extrazellulären Matrixrezeptor-Ligand-Wechselwirkung
McCain et al. B-endorphin modulates human immune activity via non-opiate receptor mechanisms
DE3586619D1 (de) Haematologische zusammensetzungen als referenz fuer drei populationen von leukocyten, verfahren zu deren herstellung und deren verwendung in ganzbluttestverfahren.
DE58903288D1 (de) Verwendung von perfluoralkylgruppen aufweisenden (meth-)acrylsaeureestern in der dentaltechnik.
DE69032618D1 (de) Bestimmung der blutströmung
IT1147852B (it) Impianto di avviso di prossimita' del suolo per aerei,con commutazione di modo in base al tempo
IT8521468A0 (it) Procedimento per ottenere interferon leucocitario alfa-2dell'uomo.
DE3788370D1 (de) Dopplersystem zur Bluttströmungsmessung während eines Herz-Lungen-Nebenschlusses und Kammerunterstützung.
Fabris et al. Fibrogenesis serum markers in patients with chronic hepatitis C treated with α-IFN
DK363088D0 (da) Dobbeltstrenget rna-korrektion af afvigende metaboliske baner, der staar i forbindelse med ukontrollerede tumorcelle- og virusvaekstcykler
LU81242A1 (fr) Composition en vue de reduire le taux de phenylalanine dans le sang,et son procede d'utilisation
PT80262A (de) Polymerisate auf basis von polyvinylencarbonat und/oder polyhydroxymethylen verfahren zu ihrer herstellung und ihre anwendung
DE68925032D1 (de) Leukozyten-adhäsions-inhibitor.
DE3888727D1 (de) Verwendung von Äthylamin-Derivaten als antihypertensive Wirkstoffe.
DE790059T1 (de) Vorrichtung zur behandlung von auto-immunkrankheiten und verfahren zur behandlung
IT1201210B (it) Metodo rapido di prova per determinare la sedimentazione del sangue venoso
FR2629916B1 (fr) Support solide pour diagnostic immunologique, son procede de traitement et application au diagnostic immunologique
Olmos et al. Impaired monocyte function in primary biliary cirrhosis
IT8720899A0 (it) Ligandi e metodi per aumentare la proliferazione di cellule b.
Tjan et al. Effects of Low Molecular Weight Serum Glycoproteins on Granulopoiesis in Rat Bone Marrow
BE865770A (fr) Esters d'acides 1,2-halogenhydrine-carboxylique leur preparation et leur utilisation dans la preparation de cyclopropane-carbaldehydes
IT1084786B (it) Miglioramenti ai catalizzatori supportati per la omo e copolimerizzazione di alfa-olefine
Anton The implications of previous work behaviour on the participation and labour supply of married Canadian women: a cross sectional analysis
KR900701834A (ko) 사람 호중구 화학주성 인자를 사람에게 투여하는 것에 의한 면역결핍 상태에 의해 유발된 질병의 치료방법
AT380636B (de) Rotationspumpe zur verwendung als blut- und herzpumpe